Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 7.8866
- Book/Share 24.2242
- PB 1.0663
- Debt/Equity 0.0788
- CurrentRatio 3.9256
- ROIC -0.3078
- MktCap 10049930123.0
- FreeCF/Share -9.0206
- PFCF -2.8714
- PE -3.4523
- Debt/Assets 0.0617
- DivYield 0
- ROE -0.2746
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
| Downgrade | MRNA | JP Morgan | Neutral | Underweight | $88 | $70 | Sept. 13, 2024 |
| Downgrade | MRNA | Oppenheimer | Outperform | Perform | -- | -- | Sept. 13, 2024 |
| Upgrade | MRNA | HSBC Securities | Reduce | Hold | -- | $82 | Aug. 28, 2024 |
News
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Cory Kasimov - Evercore ISI Courtney Breen - Bernstein Dick Gottfred - William Blair Gena Wang - Barclays Operator Good day, and thank you for standing by. Welcome to the Moderna First Quarter 2025 Conference Call.
Read More
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago.
Read More
Moderna Posts Loss, Citing Seasonality of Respiratory Business
Published: May 01, 2025 by: WSJ
Sentiment: Negative
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Read More
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027 Advancing up to 10 products toward approval, including multiple oncology candidates CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter, we continued to execute with financial discipline, …
Read More
Down 36%, Is Moderna a Buy on the Dip?
Published: April 28, 2025 by: The Motley Fool
Sentiment: Neutral
In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna (MRNA -0.79%) -- also seems to be disappearing from the world's attention.
Read More
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
What should investors do during a stock-market correction? One great strategy is to go shopping.
Read More
Can Moderna Keep the Beat Streak Alive This Earnings Season?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
Read More
Where Will Moderna Be in 5 Years?
Published: April 20, 2025 by: The Motley Fool
Sentiment: Positive
In the early days of the COVID-19 pandemic, Moderna (MRNA -1.89%) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021.
Read More
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Negative
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Published: March 31, 2025 by: Fast Company
Sentiment: Negative
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Read More
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
Published: March 31, 2025 by: Invezz
Sentiment: Negative
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Read More
Why Moderna Stock Is Plummeting Today
Published: March 31, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Moderna (MRNA -9.35%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m.
Read More
4 Things You Need to Know if You Buy Moderna Stock Today
Published: March 20, 2025 by: The Motley Fool
Sentiment: Positive
It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.
Read More
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Read More
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Published: March 07, 2025 by: Investors Business Daily
Sentiment: Positive
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. The post Why Moderna Stock Has Surged 20% This Week Despite Mixed News appeared first on Investor's Business Daily.
Read More
Moderna, Inc. (MRNA) TD Cowen 45th Annual Health Care Conference
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Corporate Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Read More
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Published: February 28, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
Read More
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
SHANGHAI , Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor calls to discuss recent developments on its mRNA therapeutic vaccine programs. The English session of the conference call will be held at 9:00 pm on March 6, 2025 Beijing Time (8:00 am U.S. Eastern Time on March 6), and the Mandarin session of the conference call will be held at 9:00 am Beijing Time on March 7, 2025 (8:00 pm U.S. Eastern Time …
Read More
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Published: February 27, 2025 by: Investors Business Daily
Sentiment: Negative
Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily.
Read More
Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports
Published: February 26, 2025 by: Reuters
Sentiment: Negative
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.
Read More
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI SK bioscience will expand its vaccine portfolio and secure global competitiveness by developing mRNA vaccines SEONGNAM, South Korea , Feb. 25, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, …
Read More
Moderna to Present at Upcoming Conferences in March 2025
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ET Barclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast: investors.modernatx.com.
Read More
CancerVax Announces Successful Tests of its Smart mRNA Technology
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells
Read More
Moderna and Other Vaccine Stocks Climb After Coronavirus News From China
Published: February 21, 2025 by: Investopedia
Sentiment: Neutral
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Read More
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Read More
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
Published: February 20, 2025 by: The Motley Fool
Sentiment: Positive
In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits.
Read More
Moderna: A Generational Opportunity for Investors in 2025
Published: February 19, 2025 by: MarketBeat
Sentiment: Positive
As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech.
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Stephane Bancel
- Employees 5800